Akero Therapeutics Announces Phase 2b HARMONY Data.

Restoring balance.
Renewing life.

Akero is pioneering novel therapies to transform the lives of people living with serious metabolic diseases.

Learn More

home_mobile_image_2

Advancing Efruxifermin (EFX) for NASH

Our flagship EFX program is designed to be a differentiated, potentially best-in-class treatment for non-alcoholic steatohepatitis (NASH)

Ongoing Clinical Studies

We have multiple ongoing clinical trials to evaluate our investigational drug, EFX, as a treatment for NASH.

Recent Press Releases from Akero

06/01/2023

Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1

05/31/2023

Akero Therapeutics to Present at the Jefferies Healthcare Conference

05/16/2023

Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock

View All

We’re looking for talented individuals driven to make a difference for patients.

See Open Positions

We’re looking for talented individuals driven to make a difference for patients.

See Open Positions